Zydus announces Phase I trials of ZYIL1 for IBD, ARDS and multiple sclerosis Studies have demonstrated that ZYIL1 can selectively supress inflammation caused by the NLRP3 inflammasome
COVID-19: Import licenses for rapid diagnostic kits of three firms cancelled, 16 suspended by DCGI The three firms are Cadila Healthcare, MDAAC International and N W Overseas, while the 16 companies include Transasia…
